Navigation Links
Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
Date:8/4/2008

Company Reiterates $3.00 per Share Proposal is Best and Final Offer

INDIANAPOLIS, Aug. 4 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today reaffirmed that its $3.00 per share purchase offer for SGX Pharmaceutical, Inc. (Nasdaq: SGXP) represents its best and final offer for the San Diego-based biotechnology company. On July 8, 2008, the two companies announced the signing of a definitive merger agreement, whereby Lilly will acquire all of the outstanding shares of SGX common stock at a price of $3.00 per share, for a total purchase price of approximately $64.0 million.

In support of the transaction, Lilly refers SGX stockholders to the definitive proxy statement that SGX filed on July 21, 2008. That definitive proxy statement includes the reasons why the board of directors of SGX voted unanimously to approve the merger agreement and to recommend that its stockholders approve the transaction. The background to the merger section of the definitive proxy statement describes the process SGX undertook to explore strategic alternatives and solicit indications of interest. As a result of these reasons, certain SGX stockholders (including certain executive officers, directors and a significant outside shareholder) who beneficially own in the aggregate, approximately 26 percent of the outstanding shares of SGX common stock, entered into a voting agreement with Lilly to vote in favor of the merger.

"We believe that the $3.00 per share purchase price represents full and fair value, and provides a very attractive premium for SGX stockholders," commented Gino Santini, Lilly senior vice president of corporate strategy and business development. "Lilly will not increase its offer price, and we are confirming that the $3.00 per share price for SGX is our best and final offer." Santini noted that the $3.00 per share price represents a sizable premium versus SGX's recent stock price performance, including a 119 percent premium to the stock's closing price immediately prior to the announcement on July 8, 2008, and a 108 percent premium over the SGX average closing price for the one month prior to the announcement. "Lilly and SGX fully intend to take this proposal to a stockholder vote at the $3.00 per share offer price," Santini concluded.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.

C-LLY

This news release contains forward-looking statements that are based on current expectations, forecasts and assumptions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. There can be no guarantee that the proposed merger transaction will be approved by SGX's shareholders, that it will receive Hart-Scott-Rodino approval, that the other conditions to closing will be met or that any of the potential benefits of the merger will be realized. Other factors that might cause such a difference include, among others, the initiation and completion of clinical trials, the FDA and other foreign review processes and other governmental regulation, Lilly's and SGX's abilities to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, the ability to effectively market products, and other risks and uncertainties described in Lilly's and SGX's filings with the Securities and Exchange Commission. Lilly and SGX undertake no duty to update forward looking statements. SGX and Lilly disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Lilly Reports Solid Second-Quarter Results
2. Lilly to Acquire SGX Pharmaceuticals
3. Lillys Connelly Appointed to the Presidents Commission on White House Fellowships
4. Lilly Employees from Nearly 50 Nations Participate in Companys First-Ever Global Day of Service
5. Lilly Backs Federal Legislation to Inform the Public on Payments to Physicians
6. Lilly Completes Final Phase of Its Indianapolis Biotechnology Complex
7. Lilly CEO Urges Policy Prescriptions to Help Ensure Public and Private Biotech Investments Generate Dividends and U.S. Job Growth
8. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
9. Lilly Reports Solid First-Quarter Results
10. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
11. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... ... Lady had been battling arthritis since the age of two and at ... owner Hannah sought the help of Dr Jeff Christiansen of Superior Veterinary Surgical ... and help with the pain of Lady’s arthritis. Dr Christiansen suggested that in conjunction ...
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, an ... and entrepreneurs, held The Future of San Diego Life Science event at the Estancia ... science community attended the event with speakers Dr. Rich Heyman, former CEO of Aragon ...
(Date:5/23/2016)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global ... Directors has approved the payment of a quarterly cash dividend ... The cash dividend of $0.24 per share will be ... record as of the close of business on June 24, ... the Board of Directors and may be adjusted as business ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... molecular nanotechnology, announced the winners for the 2015 Foresight Institute Feynman Prizes. ... given in two categories, one for experiment and the other for theory in ...
Breaking Biology Technology:
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
(Date:3/22/2016)... PROVO and SANDY, ... Screening Ontario (NSO), which operates the highest sample volume ... testing, and Tute Genomics and UNIConnect, leaders in clinical ... today announced the launch of a project to establish ... testing panel. NSO has been contracted ...
(Date:3/18/2016)... , March 18, 2016 ... Suppliers of Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure ... & security companies in the border security market and the ... and Europe has led visiongain ... companies improved success. --> defence & security ...
Breaking Biology News(10 mins):